Intellia Therapeutics’ (NTLA) Neutral Rating Reaffirmed at Wedbush

Wedbush reissued their neutral rating on shares of Intellia Therapeutics (NASDAQ:NTLA) in a research note issued to investors on Monday,Benzinga reports. Wedbush currently has a $14.00 price target on the stock.

Other equities research analysts have also recently issued research reports about the stock. William Blair reissued a “neutral” rating and set a $14.00 price target on shares of Intellia Therapeutics in a research report on Monday. Stifel Nicolaus dropped their price target on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a research report on Wednesday, September 11th. Oppenheimer dropped their price target on shares of Intellia Therapeutics from $70.00 to $60.00 and set an “outperform” rating for the company in a research report on Monday, November 11th. Evercore ISI raised shares of Intellia Therapeutics to a “strong-buy” rating in a research report on Friday, August 9th. Finally, StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a research report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $53.88.

Intellia Therapeutics Stock Up 1.4 %

NTLA stock opened at $14.17 on Monday. Intellia Therapeutics has a 52 week low of $13.54 and a 52 week high of $34.87. The firm’s fifty day moving average is $18.64 and its 200 day moving average is $22.04.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating the consensus estimate of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to analysts’ expectations of $8.28 million. The company’s quarterly revenue was down 24.1% on a year-over-year basis. During the same period in the previous year, the company earned ($1.38) EPS. On average, research analysts forecast that Intellia Therapeutics will post -5.13 earnings per share for the current fiscal year.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the sale, the chief accounting officer now directly owns 47,012 shares in the company, valued at approximately $893,698.12. This trade represents a 4.10 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Intellia Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. ARK Investment Management LLC increased its stake in Intellia Therapeutics by 5.7% during the 3rd quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company’s stock valued at $251,849,000 after purchasing an additional 659,651 shares in the last quarter. Vanguard Group Inc. increased its stake in Intellia Therapeutics by 8.9% during the 1st quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company’s stock valued at $250,168,000 after purchasing an additional 746,263 shares in the last quarter. State Street Corp increased its stake in Intellia Therapeutics by 17.9% during the 3rd quarter. State Street Corp now owns 5,143,534 shares of the company’s stock valued at $105,700,000 after purchasing an additional 780,754 shares in the last quarter. Geode Capital Management LLC increased its stake in Intellia Therapeutics by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 2,343,310 shares of the company’s stock valued at $48,164,000 after purchasing an additional 49,367 shares in the last quarter. Finally, FMR LLC increased its stake in Intellia Therapeutics by 5.0% during the 3rd quarter. FMR LLC now owns 2,339,522 shares of the company’s stock valued at $48,077,000 after purchasing an additional 111,104 shares in the last quarter. 88.77% of the stock is currently owned by institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.